Investment Rating - The report does not explicitly state an investment rating for the IVUS industry but highlights significant growth potential driven by multiple factors. Core Insights - The IVUS industry is experiencing growth due to three main factors: increasing PCI surgery volumes, rising IVUS penetration in PCI procedures, and substantial domestic replacement opportunities for imported products. Summary by Sections Market Overview - The IVUS technology is essential for guiding PCI (Percutaneous Coronary Intervention) procedures, providing real-time imaging of vascular structures and improving diagnostic accuracy [14][21]. Growth Drivers - **Increasing PCI Surgery Volumes**: The number of PCI procedures is expected to grow significantly, with China's PCI surgeries projected to increase from 1.906 million in 2024 to 4.298 million by 2030, reflecting a CAGR of 14.5% [27][28]. - **Rising IVUS Penetration**: The penetration rate of IVUS in PCI procedures in China is expected to rise from 15.4% in 2021, with projections indicating a market size growth from 1.76 billion RMB in 2024 to 5.11 billion RMB by 2030, achieving a CAGR of 19.4% [38][39]. - **Domestic Replacement Opportunities**: The IVUS market in China is currently dominated by imported brands, with local manufacturers like Beixin Life and Kaili Medical beginning to capture market share. The domestic market share for Beixin Life is projected to reach 10.6% by 2024 [39][40]. Competitive Landscape - The IVUS market is characterized by a mix of domestic and international players, with significant room for growth in domestic production and innovation. The report identifies key players such as Beixin Life and Kaili Medical as emerging competitors in the IVUS space [44][47].

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會的要求而刊 發，僅用作向香港公眾人士提供資料。 本聆訊後資料集為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即表 示 閣下知悉、接納並向本公司、其各自保薦人、整體協調人、顧問及包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所 載資料作出投資決定； (b) 在聯交所網站登載本文件或 ...

Investment Highlights - The medical device industry is transitioning from compliance requirements to core competitiveness, with green materials and digital transformation serving as dual engines for sustainable development [2][14] - The global medical device market has shown steady growth, increasing from USD 371 billion in 2015 to USD 582 billion in 2023, with a compound annual growth rate (CAGR) of approximately 6.37% [8] - China's medical device market has grown from CNY 303.8 billion to CNY 1,035.8 billion during the same period, accounting for about 25% of the global market share, making it the second-largest market after the United States [8] ESG Development - The application of biodegradable biomaterials is becoming crucial for sustainable development in the medical device industry, with materials like PLA and PHA showing promising applications in orthopedic implants and cardiovascular stents [9] - Digital twin technology is optimizing production processes, leading to a 23% reduction in energy consumption and an 18% decrease in material waste at companies like Johnson & Johnson [10] - The accessibility of medical devices is key to improving global healthcare quality, with companies like Siemens Medical providing extensive training and support to healthcare workers in low- and middle-income countries [11] Challenges and Opportunities - Domestic companies face challenges such as insufficient R&D investment, with an average of less than 5%, compared to 8%-15% in Germany and the U.S. [14] - There is a significant talent gap in green skills, with over 65% of medical device companies struggling to find qualified professionals [14] - Strengthening intellectual property protection is essential for sustainable innovation, as a 1% increase in green patent intensity could raise company valuations by 0.3%-0.5% [14] Market Performance - In the recent market review, the medical device sector recorded a positive return of +0.60%, while the chemical pharmaceutical sector saw a decline of -0.48% [15] - The valuation levels for the biopharmaceutical sector were the highest at 83.98 times, while the medical commercial sector was the lowest at 20.81 times [15]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform" [1] Core Insights - The vitamin raw material market is entering a price increase phase, with significant potential for further price rises. Key products such as VE, niacin (VB3), and folic acid (VB9) have already started to increase in price, with VA and calcium pantothenate expected to follow suit [4][6][43] - Antibiotic raw materials, particularly penicillin, have seen price increases due to India's MIP policy, with 6-APA showing the most significant rise [6][25] - The overall market for raw materials is experiencing structural recovery, with various segments showing different price trends [15][21] Summary by Sections 1. Raw Material Market Recovery - Vitamins are starting to rise from historical lows, with VE currently priced at 78 CNY/kg, showing a 35.65% increase over the past month and a 40.54% increase over three months [15][21] - Antibiotic prices, particularly for 6-APA, have increased by 17.11% in the last month, influenced by India's import price policies [15][25] - Hormones and analgesics are maintaining stable prices, while cardiovascular raw materials show no significant price fluctuations [16][33] 2. Industry Outlook and Investment Recommendations - The pharmaceutical sector has underperformed, with a 0.22% decline in the A-share pharmaceutical index, lagging behind the CSI 300 index by 0.41 percentage points [5][42] - Investment opportunities are identified in companies like Yifan Pharmaceutical, Zhejiang Medicine, and Nengte Technology, which are positioned to benefit from rising vitamin prices [6][46] - The innovative drug sector is expected to see continued growth, with companies like Innovent Biologics and 3SBio showing promise in the market [8][45] 3. Medical Devices - The medical device industry is anticipated to improve significantly in 2026, with the negative impacts of centralized procurement diminishing [49][50] - The surgical robot sector is highlighted as a key area for growth, with upcoming policy changes expected to standardize pricing and enhance market penetration [49][50]

Core Viewpoint - Boston Scientific has received approval for its OptiCross HD intravascular ultrasound diagnostic catheter, marking a significant achievement for its local production base in China, which aims to enhance the accessibility of high-end medical devices in the Chinese market [3][4]. Group 1: Company Developments - The OptiCross HD catheter is produced at Boston Scientific's new manufacturing facility in Lingang, Shanghai, which has established the first automated production line for intravascular ultrasound catheters in China, with an expected annual output of over 10,000 units [3][4]. - Boston Scientific holds a dominant position in the intravascular ultrasound diagnostic catheter market, accounting for approximately 75% of the total procurement demand in a recent centralized procurement initiative, with a total demand of about 292,400 units [4]. Group 2: Industry Context - The Chinese government has emphasized the high-quality development of medical devices in its recent work report, aligning with Boston Scientific's strategy to localize production and enhance collaboration with advanced Chinese manufacturing [3][5]. - The establishment of local manufacturing capabilities by multinational medical device companies, such as Boston Scientific, reflects the growing scale of the Chinese market and the increasing competitiveness of its manufacturing ecosystem [5][6].

Core Viewpoint - Guangzhou Kolarity Medical Equipment Co., Ltd. has been approved for IPO on the Beijing Stock Exchange, marking it as the 34th company to pass the review in 2026, with a focus on radiation therapy and rehabilitation medical devices [1][2]. Company Overview - Kolarity specializes in providing medical device solutions for radiation therapy and rehabilitation, focusing on the development, production, and sales of radiation positioning devices and rehabilitation aids [1]. - The company is primarily controlled by Lijin Technology, which holds 43.13% of the shares, and the actual controllers are Zhan Derun and his spouse Li Li, who collectively control 64.93% of the voting rights [1]. IPO Details - Kolarity plans to publicly issue up to 14.8 million shares, with a potential over-allotment option of up to 2.22 million shares, bringing the total issuance to a maximum of 17.02 million shares [2]. - The company aims to raise approximately 259.13 million yuan for projects related to radiation positioning and rehabilitation product headquarters, composite material production line upgrades, and research center construction [2]. Review and Inquiry - The review committee raised inquiries regarding the authenticity and reasonableness of Kolarity's collaboration with the American company Klarity, including the sustainability of using the "Klarity" trademark and the company's reliance on Klarity for sales channels [4]. - Questions were also posed about the sustainability of Kolarity's operating performance, particularly in light of healthcare cost control policies and market competition, as well as the company's competitive advantages in technology, funding, and scale [4].

Core Viewpoint - Tianxing Medical is a leading domestic company in the field of sports medicine, focusing on minimally invasive surgical products and aiming for a public listing on the Hong Kong Stock Exchange after multiple attempts [3][4]. Company Overview - Tianxing Medical specializes in medical devices for sports medicine, with core products including implants and surgical equipment for arthroscopic surgeries [3]. - The company has established a presence in over 3,000 hospitals in China and exports to more than 50 countries [3]. Financial Performance - Revenue increased from 147 million RMB in 2022 to 327 million RMB in 2024, with a compound annual growth rate (CAGR) of 49.1% [25]. - In the first three quarters of 2025, revenue reached 273 million RMB, with a net profit of 89.9 million RMB [25]. Market Position - As of 2024, Tianxing Medical holds a 6.5% market share, ranking as the fourth largest sports medicine device provider in China and the largest domestic provider [3][4]. - The sports medicine market in China is projected to grow from 5.4 billion RMB in 2024 to 12.1 billion RMB by 2030, with a CAGR of 14.3% [35]. Product Development - The company has developed 62 registered products, the highest number among domestic sports medicine companies, including 27 Class III and 24 Class II medical devices [24]. - Tianxing Medical's products are characterized by innovative technologies, such as absorbable implants, which are priced significantly lower than foreign counterparts [23]. Competitive Landscape - The market is dominated by international giants, but the introduction of national procurement policies has reduced foreign market share from 80% to around 50%, creating opportunities for domestic manufacturers [35][36]. - The company is positioned to benefit from favorable policies that expedite product approvals and enhance reimbursement processes for domestic devices [36]. Future Prospects - Tianxing Medical is expanding its product line to include surgical robots and AI-driven rehabilitation systems, aiming to provide comprehensive treatment and recovery solutions [31][40]. - The company is also exploring regenerative medicine, indicating a strategic move towards a more integrated business model [31].

Core Viewpoint - Medtronic has announced a definitive agreement to acquire Scientia Vascular for $550 million, aiming to enhance its product offerings in the neurovascular intervention market [2][4]. Group 1: Acquisition Details - The acquisition is characterized as a tuck-in acquisition, focusing on strengthening Medtronic's existing neurovascular product line with Scientia's devices, which include neurovascular guidewires and catheters [2][4]. - The deal is subject to customary closing conditions and includes undisclosed performance-based milestones [2]. - Medtronic plans to integrate Scientia's products into its neurovascular product system to improve the stroke treatment process [6]. Group 2: Market Context - The global stroke intervention market is becoming increasingly competitive, prompting large medical device companies to acquire firms to fill gaps in their product lines [3][14]. - The demand for neurovascular interventions is growing, with more countries establishing stroke center networks, leading to an increase in the volume of neurovascular procedures [15][22]. - The acquisition trend among major device companies indicates a shift towards building comprehensive product portfolios that cover the entire treatment process from access to therapy [21]. Group 3: Implications for the Industry - The acquisition reflects a broader trend in the neurovascular industry where companies are focusing on complete surgical solution systems rather than individual devices [20]. - In China, the neurovascular market has become one of the most active segments, with several companies expanding into access devices, indicating a competitive landscape [18][21]. - The ongoing construction of stroke centers is expected to sustain rapid growth in the neurovascular market, potentially accelerating industry consolidation [22].

Core Insights - The article narrates the true story of Robin Cavendish, who, after being diagnosed with polio and given only a few months to live, defied the odds and lived for 36 years, thanks to innovative home ventilation technology [2][22]. Group 1: The Patient's Journey - In 1958, Robin Cavendish, a 28-year-old British man, experienced a sudden health crisis that left him completely paralyzed due to polio [3][5]. - Doctors initially predicted that he would only survive for three months, leading to despair for both him and his wife, Diana [5][10]. - Diana's determination to bring Robin home from the hospital marked a pivotal moment in their lives, as she refused to accept the limitations imposed by the medical system of the time [10][13]. Group 2: Technological Innovation - Diana sought the help of engineer Teddy Hall, who created the "Cavendish Chair," the world's first portable respiratory wheelchair, allowing Robin to leave the confines of the hospital [14][15]. - The Cavendish Chair integrated a breathing machine with a powered wheelchair, enabling Robin to breathe independently while enjoying life outside [19][20]. - This innovation addressed the fundamental conflict between survival and freedom for patients reliant on mechanical ventilation [20]. Group 3: Impact on Healthcare System - Robin lived for 36 years after his initial prognosis, becoming an advocate for disability rights and influencing the UK healthcare system [22][23]. - The National Health Service (NHS) initiated a home ventilation program inspired by Robin's experience, allowing patients to receive care at home [23]. - Robin's legacy includes the establishment of charitable funds and advocacy for patient care, demonstrating the profound impact of individual stories on healthcare policy [23][25]. Group 4: Broader Implications - The story of Robin Cavendish represents a microcosm of a technological revolution in healthcare, emphasizing the importance of patient perspective in driving innovation [26]. - The evolution of home care respiratory devices has led to a global market encompassing portable ventilators, smart algorithms, and robotic care systems [26]. - The narrative highlights the human elements of determination and compassion that often underpin technological advancements in medicine [26].

Core Viewpoint - The Chinese medical device industry has maintained a high level of business development (BD) activity over the past three months, with various forms of collaboration emerging, including mergers and acquisitions, technology partnerships, channel authorizations, and industry chain collaborations, indicating an acceleration in capital integration and industrial synergy within the sector [2][22]. Overview of BD Events - Approximately 30 BD events in the medical device sector were recorded from December 2025 to March 2026, with significant activity in cardiovascular and interventional devices, as well as IVD industry chain collaborations [5][6]. Event Type Structure - The BD activities are characterized by a clear structure, with strategic and technical collaborations being the most prevalent, involving joint R&D, supply chain collaboration, and channel partnerships. Equity acquisitions and asset mergers, while fewer in number, have a more substantial impact on the industry landscape [6][19]. Notable Transactions - Key transactions include: - Heartlink Medical's acquisition of Micro-Invasive Cardiac Management for $680 million, expanding its product portfolio to a comprehensive cardiovascular platform [10][12]. - Midea Medical's acquisition of Carestream International's imaging assets, enhancing its global market capabilities [11][12]. - Aibo Medical's acquisition of 68.31% of Demai Medical for 683 million yuan, entering the sports medicine device sector [12][13]. - Guichuang Tongqiao's investment in German company Optimed, reflecting the trend of Chinese interventional device companies integrating European technology and market resources [13][18]. - Baiyang Medical's joint venture with ZAP Surgical to establish a production base for the ZAP-X robotic system, showcasing collaboration in high-end medical equipment [14][18]. Trends in BD Activities - Overseas acquisitions have become a crucial path for Chinese companies to acquire technology, with many transactions involving foreign assets [15][18]. - There is a noticeable increase in collaborative efforts focused on supply chain and industry chain synergy, indicating a shift from single product competition to ecosystem collaboration [19][22]. - Channel partnerships remain a significant method for multinational companies to enter the Chinese market, reflecting the expanding scale of the domestic medical device market [20][22]. - Collaborations centered around technology platforms are on the rise, indicating a transition towards systematic medical technology platform development [21][22].